6N6O
Crystal structure of the human TTK in complex with an inhibitor
Summary for 6N6O
Entry DOI | 10.2210/pdb6n6o/pdb |
Related | 6B4W |
Descriptor | Dual specificity protein kinase TTK, 4-({5-chloro-4-[(cis-4-hydroxy-4-methylcyclohexyl)oxy]-7H-pyrrolo[2,3-d]pyrimidin-2-yl}amino)-N,N-dimethyl-3-{[(2R)-1,1,1-trifluoropropan-2-yl]oxy}benzamide, PENTAETHYLENE GLYCOL, ... (5 entities in total) |
Functional Keywords | protein kinase activity protein serine/threonine/tyrosine kinase activity atp binding protein phosphorylation mitotic cell cycle checkpoint chromosome separation, signaling protein |
Biological source | Homo sapiens (Human) |
Total number of polymer chains | 1 |
Total formula weight | 33783.12 |
Authors | Fenalti, G. (deposition date: 2018-11-26, release date: 2019-05-15, Last modification date: 2019-05-22) |
Primary citation | Riggs, J.R.,Elsner, J.,Cashion, D.,Robinson, D.,Tehrani, L.,Nagy, M.,Fultz, K.E.,Krishna Narla, R.,Peng, X.,Tran, T.,Kulkarni, A.,Bahmanyar, S.,Condroski, K.,Pagarigan, B.,Fenalti, G.,LeBrun, L.,Leftheris, K.,Zhu, D.,Boylan, J.F. Design and Optimization Leading to an Orally Active TTK Protein Kinase Inhibitor with Robust Single Agent Efficacy. J.Med.Chem., 62:4401-4410, 2019 Cited by PubMed: 30998356DOI: 10.1021/acs.jmedchem.8b01869 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (2.6 Å) |
Structure validation
Download full validation report